During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR T-cell therapies in multiple myeloma and beyond.
This is the second article of a 2-part series. See the first part here.
CASE SUMMARY
Two Years Later
One Year Later
Targeted Oncology: What would the quality of life (QOL) be for this patient if she received ide-cel (idecabtagene vicleucel; Abecma)?
Saad Z. Usmani, MD, FACP, MBA: The QOL of patients after CAR T recovery is quite remarkable.1 They're not on any maintenance treatment and so, they have really good quality of life. They're just coming in once a month for their laboratory tests and to see every other month and they do fine. You can watch for the disease relapse based on symptoms or laboratory results.
What have the real-world results for ide-cel shown?
In the real world, there has been a CIBMTR study that was published on 600 or so patients who have received ide-cel and the patterns were very similar to what was observed in the clinical trials in terms of cytokine release syndrome, grading, and neurologic adverse events.2 Patients who get to a complete response or better, the anticipated median progression-free survival for those patients as well is very much in line with what's been [published in clinical trials]. Patients who have had prior BCMA treatments, such as bispecific antibodies or antibody-drug conjugates, still respond to ide-cel, and BCMA loss is not a common mechanism of [resistance] that we see in patients, so you can rechallenge patients with different BCMA-directed treatments. There's a difference in how much mileage you get out of that intervention. It's not the same as someone who is not BCMA-exposed, but you still get some bang for the buck.
Is CAR T-cell therapy a reasonable option for community centers?
For CAR T-cell therapy, we eventually want to get to a place where it's more commonly available, that even smaller centers will be able to deliver that product and have that efficacy. We're focused on myeloma right now, but…there are CAR T cells coming for lung cancer and breast cancer. All the good things start in hematology, and then get expanded to other malignancies. Once you get [options like] a relapsed non–small cell lung cancer CAR T cell, the community hospitals will develop mechanisms to manage those patients and build smaller programs.
I think the cost of therapy will also decline as these technologies become more readily available and even potentially have point-of-care treatment. I'm talking about the future; we started with hematology, with some lymphomas and myeloma, but I can tell you that more than half of the CAR T that we have on service at Memorial Sloan Kettering Cancer Center are the experimental solid tumor CAR T cells. That train is coming and so it's not going to be just at academic centers. There's no way possible, even with all the resources that big centers have, that you can manage that kind of capacity. We will never be able to have 5000-bed hospitals just focused on managing that kind of volume. And 80% of the cancer care happens in the community, so that's the only way to move forward, honestly.
References:
1. Delforge M, Patel KK, Eliason L, et al. Effects of idecabtagene vicleucel (ide-cel) versus standard tegimens on health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) who had received 2–4 prior regimens: updated results from the phase 3 KarMMa-3 trial. Blood. 2023;142(1):96. doi:10.1182/blood-2023-179152
2. Sidana S, Ahmed N, Akhtar OS, et al. Real world outcomes with idecabtagene vicleucel (Ide-Cel) CAR-T cell therapy for relapsed/refractory multiple myeloma. Blood. 2023;142(suppl 1):1027. doi:10.1182/blood-2023-181762
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More
FDA Accepts BLA for Belantamab Mafodotin Combinations in R/R Multiple Myeloma
November 25th 2024The FDA has accepted the BLA for belantamab mafodotin in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma, as supported by DREAMM-7 and DREAMM-8 data.
Read More